Modality
Fusion Protein
MOA
DLL3 ADC
Target
BCL-2
Pathway
Fibrosis
TTR AmyloidosisOvarian CaPBC
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
~Oct 2021
→ ~Jan 2023
Phase 2
Apr 2023
→ Nov 2026
Phase 2Current
NCT07171947
2,462 pts·TTR Amyloidosis
2023-04→2026-11·Completed
2,462 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-117mo awayPh3 Readout· TTR Amyloidosis
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2/3
Complet…
Catalysts
Ph3 Readout
2026-11-11 · 7mo away
TTR Amyloidosis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07171947 | Phase 2/3 | TTR Amyloidosis | Completed | 2462 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| Zenonaritide | Arvinas | Phase 1/2 | BCL-2 |